Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) is a clinical-stage biotechnology company pioneering IgM antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. This page serves as the definitive source for official news, press releases, and financial updates directly from the company and verified partners.
Investors and stakeholders will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations with global pharmaceutical leaders. The curated content includes earnings reports, research breakthroughs, and pipeline advancements related to the company’s proprietary IgM platform, which enables multispecific antibody engineering.
Bookmark this page to track IGM Biosciences’ progress in developing novel therapies that leverage the unique binding capabilities of IgM antibodies. Visit regularly for unfiltered access to critical updates that may impact long-term investment strategies and sector analysis.
IGM Biosciences (IGMS) announced the discontinuation of two key pipeline programs: imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) for autoimmune diseases. The decision comes after interim data from Phase 1b studies showed insufficient B cell depletion in rheumatoid arthritis and systemic lupus erythematosus patients.
As part of this strategic update, the company is implementing significant restructuring measures, including a 73% workforce reduction. The company reported unaudited cash and investments of $183.8 million as of December 31, 2024, and is currently evaluating internal options and potential strategic alternatives to maximize shareholder value.
IGM Biosciences reported Q3 2024 financial results and corporate updates. The company is advancing clinical trials for imvotamab in autoimmune diseases, with initial data expected by mid-2025. Cash position stands at $218.8M as of September 30, 2024. Q3 net loss was $61.4M ($1.01 per share). The company expects 2024 operating expenses of $215-225M and projects cash runway into 2027. IGM-2644 is expected to enter clinical trials for generalized myasthenia gravis by end of 2024. The company has successfully completed the third dose cohort for rheumatoid arthritis trials and continues enrollment in systemic lupus erythematosus and myositis studies.
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotechnology company focused on engineered IgM antibodies, has announced its participation in three major investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), the Stifel Healthcare Conference in New York (Nov. 19), and the Jefferies London Healthcare Conference in London (Nov. 21).
Live webcasts of all presentations will be accessible through the company's investor relations website, with recordings available for 90 days post-presentation.
IGM Biosciences (Nasdaq: IGMS) announced a strategic pivot to focus exclusively on developing T cell engaging IgM antibodies for autoimmune diseases. Key points include:
1. Prioritizing pipeline of T cell engagers, including imvotamab for rheumatoid arthritis and systemic lupus erythematosus.
2. Appointment of Mary Beth Harler, M.D. as CEO and Board member.
3. Cash runway extended into 2027.
4. Minimizing future spending on oncology candidates, including aplitabart.
5. Leadership changes: Fred Schwarzer and Bruce Keyt stepping down from current roles, remaining as consultants; Chris Takimoto leaving the company.
The company will host a conference call and webcast to discuss the strategic pivot on September 30, 2024, at 4:30 p.m. EDT.
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotech company specializing in engineered IgM antibodies, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. CEO Fred Schwarzer and Head of Research & Autoimmunity, Dr. Mary Beth Harler, will engage in a fireside chat on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
The event will be accessible via a live webcast on the company's investor relations website. Interested parties can view the presentation through the 'Events and Presentations' page. For those unable to attend live, a replay will be available on the company's website for 90 days following the presentation, ensuring widespread access to this important industry event.
IGM Biosciences (Nasdaq: IGMS) announced its Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment of 127 patients in the randomized colorectal cancer trial for aplitabart, with top-line PFS results expected by the end of Q1 2025
- Cleared second dose cohort in imvotamab rheumatoid arthritis trial and first dose cohort in systemic lupus erythematosus trial
- Q2 2024 financial results: $256.4 million in cash and investments, $1.3 million in collaboration revenue, $42.0 million in R&D expenses, and a net loss of $47.9 million ($0.79 per share)
- Full year 2024 guidance: GAAP operating expenses of $210-220 million, collaboration revenue of ~$2 million, and expected year-end cash balance of ~$180 million
IGM Biosciences, a clinical-stage biotech firm, will present at the Jefferies Healthcare Conference. CEO Fred Schwarzer will participate in a fireside chat on June 5, 2024, at 2:30 p.m. EDT in New York. The event will be webcast live via the company's website and archived for 90 days.
IGM Biosciences, Inc. (Nasdaq: IGMS) exceeded enrollment targets in clinical trials for aplitabart in colorectal cancer and imvotamab in rheumatoid arthritis. Financially, the company reported $293.8 million in cash and investments, with net loss of $49.8 million for the first quarter of 2024. The company expects full year 2024 GAAP operating expenses of $210-220 million and collaboration revenue of $63 million.
IGM Biosciences, Inc. (Nasdaq: IGMS) will be participating in a fireside chat at the 2024 RBCCM Global Healthcare Conference on May 14, 2024. The event will be webcasted live and available for replay on the company's website for 90 days.
